Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth In Vivo than Either Drug Alone.

Tran LNK, Kichenadasse G, Morel KL, Lavranos TC, Klebe S, Lower KM, Ormsby RJ, Elliot DJ, Sykes PJ.

In Vivo. 2019 Jan-Feb;33(1):99-108. doi: 10.21873/invivo.11445.

2.

Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma.

White R, Pulford E, Elliot DJ, Thurgood LA, Klebe S.

J Proteomics. 2019 Feb 10;192:374-382. doi: 10.1016/j.jprot.2018.09.018. Epub 2018 Oct 6.

PMID:
30300743
3.

Homoarginine and inhibition of human arginase activity: kinetic characterization and biological relevance.

Tommasi S, Elliot DJ, Da Boit M, Gray SR, Lewis BC, Mangoni AA.

Sci Rep. 2018 Feb 27;8(1):3697. doi: 10.1038/s41598-018-22099-x.

4.
5.

In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes.

Bendikov MY, Miners JO, Simpson BS, Elliot DJ, Semple SJ, Claudie DJ, McKinnon RA, Gillam EMJ, Sykes MJ.

Xenobiotica. 2017 Jun;47(6):461-469. doi: 10.1080/00498254.2016.1203041. Epub 2016 Jul 14.

PMID:
27412850
6.

PTESFinder: a computational method to identify post-transcriptional exon shuffling (PTES) events.

Izuogu OG, Alhasan AA, Alafghani HM, Santibanez-Koref M, Elliott DJ, Jackson MS.

BMC Bioinformatics. 2016 Jan 13;17:31. doi: 10.1186/s12859-016-0881-4. Erratum in: BMC Bioinformatics. 2016;17:92. Elliot, David J [corrected to Elliott, David J].

7.

Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies.

Chau N, Elliot DJ, Lewis BC, Burns K, Johnston MR, Mackenzie PI, Miners JO.

J Pharmacol Exp Ther. 2014 Apr;349(1):126-37. doi: 10.1124/jpet.113.212258. Epub 2014 Jan 23.

PMID:
24459244
8.

Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

J Urol. 2012 Oct;188(4):1131-6. doi: 10.1016/j.juro.2012.06.009. Epub 2012 Aug 15.

9.

Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.

Wattanachai N, Tassaneeyakul W, Rowland A, Elliot DJ, Bowalgaha K, Knights KM, Miners JO.

Drug Metab Dispos. 2012 May;40(5):982-9. doi: 10.1124/dmd.111.044057. Epub 2012 Feb 13.

PMID:
22331994
10.

Application of the fluorescent probe 1-anilinonaphthalene-8-sulfonate to the measurement of the nonspecific binding of drugs to human liver microsomes.

McLure JA, Birkett DJ, Elliot DJ, Williams JA, Rowland A, Miners JO.

Drug Metab Dispos. 2011 Sep;39(9):1711-7. doi: 10.1124/dmd.111.039354. Epub 2011 May 24.

PMID:
21610127
11.

Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation.

Miners JO, Bowalgaha K, Elliot DJ, Baranczewski P, Knights KM.

Drug Metab Dispos. 2011 Apr;39(4):644-52. doi: 10.1124/dmd.110.037036. Epub 2011 Jan 18.

PMID:
21245288
12.

The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution.

MacKenzie PI, Rogers A, Elliot DJ, Chau N, Hulin JA, Miners JO, Meech R.

Mol Pharmacol. 2011 Mar;79(3):472-8. doi: 10.1124/mol.110.069336. Epub 2010 Nov 18.

PMID:
21088224
13.

In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans.

Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, Miners JO.

J Pharmacol Exp Ther. 2010 Aug;334(2):609-18. doi: 10.1124/jpet.110.167916. Epub 2010 May 18.

PMID:
20484152
14.

In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.

Polasek TM, Sadagopal JS, Elliot DJ, Miners JO.

Eur J Clin Pharmacol. 2010 Mar;66(3):275-83. doi: 10.1007/s00228-009-0760-2. Epub 2009 Dec 11.

PMID:
20012430
15.

Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.

Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, Sokoll LJ.

J Urol. 2010 Feb;183(2):534-8. doi: 10.1016/j.juro.2009.10.003. Epub 2009 Dec 14.

PMID:
20006883
16.

Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.

Knights KM, Winner LK, Elliot DJ, Bowalgaha K, Miners JO.

Br J Clin Pharmacol. 2009 Sep;68(3):402-12. doi: 10.1111/j.1365-2125.2009.03469.x.

17.

In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway.

Kerdpin O, Knights KM, Elliot DJ, Miners JO.

Biochem Pharmacol. 2008 Jul 15;76(2):249-57. doi: 10.1016/j.bcp.2008.04.014. Epub 2008 May 1.

PMID:
18541222
18.

The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9.

Rowland A, Elliot DJ, Knights KM, Mackenzie PI, Miners JO.

Drug Metab Dispos. 2008 May;36(5):870-7. doi: 10.1124/dmd.107.019885. Epub 2008 Feb 6.

PMID:
18256202
19.

Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates.

Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO.

Pharmacogenet Genomics. 2007 Dec;17(12):1017-29.

PMID:
18004206
20.

Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4.

Kubota T, Lewis BC, Elliot DJ, Mackenzie PI, Miners JO.

Mol Pharmacol. 2007 Oct;72(4):1054-62. Epub 2007 Jul 17.

PMID:
17636046
21.

Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.

Elliot DJ, Suharjono, Lewis BC, Gillam EM, Birkett DJ, Gross AS, Miners JO.

Br J Clin Pharmacol. 2007 Oct;64(4):450-7. Epub 2007 May 22.

22.

Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation.

Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, Miners JO.

J Pharmacol Exp Ther. 2007 Apr;321(1):137-47. Epub 2007 Jan 19.

PMID:
17237258
23.

Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation.

Lewis BC, Mackenzie PI, Elliot DJ, Burchell B, Bhasker CR, Miners JO.

Biochem Pharmacol. 2007 May 1;73(9):1463-73. Epub 2006 Dec 22.

PMID:
17223084
24.
25.

Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9.

Kerdpin O, Elliot DJ, Mackenzie PI, Miners JO.

Drug Metab Dispos. 2006 Dec;34(12):1950-3. Epub 2006 Sep 19.

PMID:
16985098
26.

An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.

Polasek TM, Elliot DJ, Somogyi AA, Gillam EM, Lewis BC, Miners JO.

Br J Clin Pharmacol. 2006 May;61(5):570-84.

27.

In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction.

Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO.

Drug Metab Dispos. 2006 Jun;34(6):1055-62. Epub 2006 Mar 24.

PMID:
16565174
28.

Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation.

Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, Miners JO.

Br J Clin Pharmacol. 2006 Apr;61(4):427-39.

29.

Measurement of human cytochrome P4501A2 (CYP1A2) activity in vitro.

Polasek TM, Elliot DJ, Miners JO.

Curr Protoc Toxicol. 2006;Chapter 4:Unit4.19. doi: 10.1002/0471140856.tx0419s27.

PMID:
23045133
31.
32.

Electrochemical characterisation of the human cytochrome P450 CYP2C9.

Johnson DL, Lewis BC, Elliot DJ, Miners JO, Martin LL.

Biochem Pharmacol. 2005 May 15;69(10):1533-41.

PMID:
15857618
33.

Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro.

Polasek TM, Elliot DJ, Lewis BC, Miners JO.

J Pharmacol Exp Ther. 2004 Dec;311(3):996-1007. Epub 2004 Aug 10.

PMID:
15304522
34.

Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity.

Kerdpin O, Elliot DJ, Boye SL, Birkett DJ, Yoovathaworn K, Miners JO.

Biochemistry. 2004 Jun 22;43(24):7834-42.

PMID:
15196026
35.

Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9.

Boye SL, Kerdpin O, Elliot DJ, Miners JO, Kelly L, McKinnon RA, Bhasker CR, Yoovathaworn K, Birkett DJ.

Xenobiotica. 2004 Jan;34(1):49-60.

PMID:
14742136

Supplemental Content

Loading ...
Support Center